Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Mabwell (迈威生物) A+H: Moderate Upside but Connect Event Ahead

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Mabwell (Shanghai) Bioscience / Equity Capital Markets

<ul>
<li>Mabwell raised HKD 1302m (USD 166m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday April 27th, 2026.</li>
<li>In our previous note, we looked at the company's fundamentals and the valuation.</li>
<li>In this note, we provide an update for the IPO before its trading debut.</li>
</ul>


Mabwell raised HKD 1302m (USD 166m) from its global offering and will list on the Hong Kong Stock Exchange on Tuesday April 27th, 2026.
In our previous note, we looked at the company's fundamentals and the valuation.
In this note, we provide an update for the IPO before its trading debut.


Shenzhen Woer Heat-Shrinkable Material (9981 HK)

Mabwell (Shanghai) Bioscience

Mabwell (迈威生物) A+H IPO Trading